Allos Investor Tries To Block $686M AMAG Merger
An Allos Therapeutics Inc. shareholder lodged a class action in Delaware court Friday over the company's planned $686 million all-stock merger with AMAG Pharmaceuticals Inc., saying the deal would leave Allos...To view the full article, register now.
Already a subscriber? Click here to view full article